Metagenomi Inc (MGX) Actualités

Metagenomi Presents Novel, Highly Specific and Efficient Adenine Base Editors for Broad Genome Editing at ESGCT

Metagenomi Adenine Base Editors (ABEs) demonstrated over 95% genome targetability Simultaneous ABE triplex...

Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGX

Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before...

Metagenomi Presents Compact SMART Editing Platform at AIChE 7th International Conference on CRISPR Technologies

Poster presentation highlights SMART adenine base editors (ABEs)small enough to be packaged into a single...

Shareholders that lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action - MGX

Shareholders that lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 25, 2024 in Metagenomi Lawsuit - MGX

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 25, 2024 in Metagenomi...

Shareholders of Metagenomi, Inc. Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGX

Shareholders of Metagenomi, Inc. Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your...

Investors who lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action - MGX

Investors who lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action...

Metagenomi to Present at Chardan's 8th Annual Genetic Medicines Conference

EMERYVILLE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months

Twelve-month durability data from Metagenomi’s ongoing nonhuman primate (NHP) study in hemophilia A remains...

Metagenomi Presents AI-Enabled Advancements of SMART Editing Platform at the Cold Spring Harbor Laboratory CRISPR Frontiers Conference

AI-generated, compact SMART nucleases demonstrated robust genome editing activity in vitro in mammalian cells...

Metagenomi to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic...

Form 8-K - Current report

Metagenomi Reports Business Updates and Second Quarter 2024 Financial Results

Declared development candidate MGX-001 for the treatment of hemophilia A; plans to present 12-month NHP...